Author

Michael Ciarametaro

Observed names: Ciarametaro, Michael, M Ciarametaro, M. Ciarametaro, Michael Ciarametaro, MBA;O’Brien,John;

Observed institution: National Pharmaceutical Council

OpenAlex ID: A5110691753

The Effect of Medical Technology Innovations on Patient Outcomes, 1990-2015: Results of a Physician Survey

2018 · David E. Wamble, Michael Ciarametaro, et al. · Journal of Managed Care & Specialty Pharmacy · 43

PDF

No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals

2016 · Nicole B. Gabler, Naihua Duan, et al. · Trials · 40

PDF

Health Care Spending Effectiveness: Estimates Suggest That Spending Improved US Health From 1996 To 2016

2022 · Marcia R. Weaver, Jonah Joffe, et al. · Health Affairs · 27

Insurance switching and mismatch between the costs and benefits of new technologies.

2017 · David Cutler, Michael Ciarametaro, et al. · PubMed · 12

Do Patient Preferences Align With Value Frameworks? A Discrete-Choice Experiment of Patients With Breast Cancer

2020 · Ilene L. Hollin, Juan Marcos González, et al. · MDM Policy & Practice · 10

PDF

What’s Been The Bang For The Buck? Cost-Effectiveness Of Health Care Spending Across Selected Conditions In The US

2019 · David Wamble, Michael Ciarametaro, et al. · Health Affairs · 10

The Dollar or Disease Burden: Caps on Healthcare Spending May Save Money, but at What “Cost” to Patients?

2021 · Michael Ciarametaro, Katherine Houghton, et al. · Value in Health · 9

Concerns Around Budget Impact Thresholds: Not All Drugs Are the Same

2017 · Michael Ciarametaro, Susan Abedi, et al. · Value in Health · 8

Medicaid best price reforms to enable innovative payment models for cell and gene therapies

2022 · Casey Quinn, Michael Ciarametaro, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 5

A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures

2017 · James Chambers, Elle Pope, et al. · Value in Health · 4

Value-based performance arrangements for chronic conditions: an economic simulation of Medicaid Drug Rebate Program reforms

2023 · Casey Quinn, Michael Ciarametaro, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 3

PDF

Evaluating the Importance of Heterogeneity of Treatment Effect: Variation in Patient Utilities Can Influence Choice of the “Optimal” Oral Anticoagulant for Atrial Fibrillation

2016 · Christopher G. Cameron, Patricia G. Synnott, et al. · Value in Health · 3

PDF

What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States

2022 · William Herring, Michael Ciarametaro, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2

Impact of formulary restrictions on medication intensification in diabetes treatment.

2018 · Bruce C Stuart, Julia F Slejko, et al. · PubMed · 2

Good health policy requires high-quality evidence. Let’s remember that with drug pricing.

2022 · Michael Ciarametaro, MBA;O’Brien,John; · The American Journal of Managed Care · 1

EE408 The Effect of Medical Innovation on the Cost-Effectiveness of COVID 19-Related Policies in the United States Using a Sir Model

2022 · A Atherly, E Van Den Broek-Altenburg, et al. · Value in Health · 1

PDF

Utilization of High-Cost Interventions for Targeted Clinical Conditions During the Early Stages of ACO Development in a Commercially Insured Population

2018 · Siting Zhou, Michael Ciarametaro, et al. · Population Health Management · 1

Availability of Cost Effectiveness Information on the Highest-cost Drugs and Procedures in the United States

2016 · K. Bungay, J.T. Cohen, et al. · Value in Health · 1

HPR64 ICER Thresholds in Cost-Utility Analysis: Assessing Conceptual Relevance and Practical Adequacy for Drug Reimbursement Decision-Making in The US

2025 · Ulrich Neumann, Michael Ciarametaro, et al. · Value in Health

What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States

2022 · Herring, William, Ciarametaro, Michael, et al. · Figshare

Health spending expenditures for commercial plans are predominantly concentrated among a small population of high-intensity consumers across settings of care

2021 · Michael Ciarametaro, Michael Kleinrock, et al. · Journal of Managed Care & Specialty Pharmacy

Assessing the Effect of Formulary Restrictions on Antihyperglycemic Drugs

2016 · J.F. Slejko, J. Rueda, et al. · Value in Health

Additional file 1: Table S1. of No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals

2016 · Gabler, Nicole, Duan, Naihua, et al. · Figshare

Utilization, Costs And Reimbursement Of Inpatient And Ambulatory Treatment Of Acute Bacterial Skin And Skin Structure Infections Among The Medicare Fee-For-Service Population

2014 · K LaPensee, W Fan, et al. · Value in Health

Utilization, Costs And Reimbursement Of Inpatient Treatment Of Acute Bacterial Skin And Skin Structure Infections Among The Medicare Fee-For-Service Population

2014 · K LaPensee, W Fan, et al. · Value in Health

Works count: 33

Citation count: 182

H-index: 8

I10-index: 6